Expanded Access Program With Nivolumab Therapy for Treatment of Advanced/Metastatic SqNSCLC or Non-SqNSCLC After One Prior Systemic Regimen

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: * Sq or Non-Sq NSCLC, Stage IIIb/IV (histologically or cytologically confirmed) * Relapsed after 1 prior platinum-based systemic treatment * Eastern Cooperative Oncology Group (ECOG) Performance Status \< 2 * CNS metastasis must be treated and returned to baseline at least 2 weeks before first dose of nivolumab and off steroids or using stable or decreasing dose of \< 10 mg prednisone or equivalent * Prior chemotherapy, Tyrosine Kinase Inhibitor (TKI) therapy or Immunotherapy (tumor vaccine, cytokine or growth factor to control cancer) must be completed at least 2 weeks before first nivolumab dose Exclusion Criteria: * CNS metastases (untreated and/or symptomatic) * Carcinomatous meningitis * ECOG Performance status \> 3 * Corticosteroids \> 10 mg prednisolone/day (or equivalent) * Prior treatment with anti-PD-1, anti-PD-L-1, anti-PDL2, anti-CT137 or anti-CTLA antibody, including ipilimumab or any other drugs specifically targeting T cell costimulation or checkpoint pathways